Operator of an immunotherapy company that develops bi-specific antibodies combining cancer-targeting and viral immunity activation modules to treat various cancers. This approach addresses the low response rates of existing immunotherapies by effectively labeling cancer cells as virally infected, thereby enhancing immune system activation for improved treatment outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Existing cancer immunotherapies often suffer from low response rates, as they fail to effectively stimulate the immune system to recognize and attack cancer cells. This is because cancer cells are not easily identified as foreign or dangerous by the immune system.
Solution
This company is developing bi-specific antibodies that combine cancer-targeting modules with viral immunity activation modules to treat various cancers. The antibodies are designed to target cancer cells and label them as if they were virally infected. By mimicking a viral infection, the bi-specific antibodies harness the potent anti-viral immune response to fight the tumor. This approach aims to improve treatment outcomes by more effectively activating the immune system to eliminate cancer cells.
Target Audience
The primary target audience includes patients with various types of cancer who are not responding well to existing immunotherapies, as well as oncologists and researchers seeking more effective cancer treatment options.
Features
- Bi-specific antibody composed of a cancer-targeting module and a viral immunity activation module.
- Switchable targeting arms and viral moieties to attack different tumor types.
- Designed to specifically target cancer cells, minimizing off-target effects.
- Leverages the power of viral immunity to enhance the anti-cancer immune response.
- AI-driven platform for antibody design and optimization.